A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD

Conclusions FF/VI combination was associated with a decrease of the rate of COPD exacerbations, without affecting mortality or cardiovascular outcomes in patients with moderate to severe stable COPD. Also, the use of FF was associated with an increased risk of pneumonia.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research